A 24-week, randomised, double-blind, double-dummy parallel-group, multi-centre, active-controlled study to evaluate efficacy and safety of remogliflozin etabonate in subjects with type-2 diabetes mellitus.

Trial Profile

A 24-week, randomised, double-blind, double-dummy parallel-group, multi-centre, active-controlled study to evaluate efficacy and safety of remogliflozin etabonate in subjects with type-2 diabetes mellitus.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Jan 2018

At a glance

  • Drugs Remogliflozin etabonate (Primary) ; Dapagliflozin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Glenmark Pharmaceuticals Ltd
  • Most Recent Events

    • 08 Jan 2018 Status changed from not yet recruiting to recruiting.
    • 13 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top